Health-care companies rose as traders rotated into high-risk areas such as biotechnology.

Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its portfolio beyond Covid-19.

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine